All In Biotech

Drug Trial Radar · NCT04004429

A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Aug 26, 2019

Primary completion

Nov 16, 2021

Study completion Nov 16, 2021

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
First posted
Jul 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) \> 22, who are to start up-titration with methotrexate.

Conditions

  • Rheumatoid Arthritis

Interventions

  • 50 mg AP1189Drug

    50 mg AP1189 powder in bottle

  • AP1189Drug

    100 mg AP1189 powder in bottle

  • PlaceboDrug

    Placebo powder in bottle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinical Disease Activity Index (CDAI)Time frame: 4 weeks
  2. Change in Clinical Disease Activity Index (CDAI)Time frame: 4 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Aarhus Universitetshospital

    Aarhus, Denmark

  • Diakonhjemmet Sykehus

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.